Clinical Trials | March 03, 2026
AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
This study evaluated a difficult-to-treat Crohn's disease patient population
This study evaluated a difficult-to-treat Crohn's disease patient population
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
